Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.
GSK wins FDA approval for long-acting asthma drug
GSK secured FDA approval for an inflammatory disease drug that it says could reach £3 billion ($4 billion) in peak sales. The agency greenlit depemokimab



